Irritable bowel syndrome, inflammatory bowel disease and the microbiome
Year: 2013
Type: review
Abstract: PURPOSE OF REVIEW: The review aims to update the reader on current developments in our understanding of how the gut microbiota impact on inflammatory bowel disease and the irritable bowel syndrome. It will also consider current efforts to modulate the microbiota for therapeutic effect. RECENT FINDINGS: Gene polymorphisms associated with inflammatory bowel disease increasingly suggest that interaction with the microbiota drives pathogenesis. This may be through modulation of the immune response, mucosal permeability or the products of microbial metabolism. Similar findings in irritable bowel syndrome have reinforced the role of gut-specific factors in this 'functional' disorder. Metagenomic analysis has identified alterations in pathways and interactions with the ecosystem of the microbiome that may not be recognized by taxonomic description alone, particularly in carbohydrate metabolism. Treatments targeted at the microbial stimulus with antibiotics, probiotics or prebiotics have all progressed in the past year. Studies on the long-term effects of treatment on the microbiome suggest that dietary intervention may be needed for prolonged efficacy. SUMMARY: The microbiome represents 'the other genome', and to appreciate its role in health and disease will be as challenging as with our own genome. Intestinal diseases occur at the front line of our interaction with the microbiome and their future treatment will be shaped as we unravel our relationship with it.
Authors: Giles Major, Robin Spiller
Institutions: University of Nottingham, Queen's Medical Centre
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: irritable bowel syndrome, inflammatory bowel disease, gut microbiota, microbiome, genetic polymorphism, immune response, mucosal permeability, microbial metabolites, carbohydrate metabolism, metagenomics, probiotics, prebiotics, antibiotics, dietary intervention, microbiota-targeted therapy
Open Access status: hybrid
Award: G8246481751
OpenAlex ID: W2163784760
